Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia

S. Vodret, G. Bortolussi, AB. Schreuder, J. Jašprová, L. Vitek, HJ. Verkade, AF. Muro,

. 2015 ; 5 (-) : 16203. [pub] 20151106

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16027994

Therapies to prevent severe neonatal unconjugated hyperbilirubinemia and kernicterus are phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity and mortality risks. Neurotoxicity is caused by the fraction of unconjugated bilirubin not bound to albumin (free bilirubin, Bf). Human serum albumin (HSA) administration was suggested to increase plasma bilirubin-binding capacity. However, its clinical use is infrequent due to difficulties to address its potential preventive and curative benefits, and to the absence of reliable markers to monitor bilirubin neurotoxicity risk. We used a genetic mouse model of unconjugated hyperbilirubinemia showing severe neurological impairment and neonatal lethality. We treated mutant pups with repeated HSA administration since birth, without phototherapy application. Daily intraperitoneal HSA administration completely rescued neurological damage and lethality, depending on dosage and administration frequency. Albumin infusion increased plasma bilirubin-binding capacity, mobilizing bilirubin from tissues to plasma. This resulted in reduced plasma Bf, forebrain and cerebellum bilirubin levels. We showed that, in our experimental model, Bf is the best marker to determine the risk of developing neurological damage. These results support the potential use of albumin administration in severe acute hyperbilirubinemia conditions to prevent or treat bilirubin neurotoxicity in situations in which exchange transfusion may be required.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027994
003      
CZ-PrNML
005      
20161005131417.0
007      
ta
008      
161005s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/srep16203 $2 doi
024    7_
$a 10.1038/srep16203 $2 doi
035    __
$a (PubMed)26541892
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vodret, Simone $u International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149 - Trieste, Italy.
245    10
$a Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia / $c S. Vodret, G. Bortolussi, AB. Schreuder, J. Jašprová, L. Vitek, HJ. Verkade, AF. Muro,
520    9_
$a Therapies to prevent severe neonatal unconjugated hyperbilirubinemia and kernicterus are phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity and mortality risks. Neurotoxicity is caused by the fraction of unconjugated bilirubin not bound to albumin (free bilirubin, Bf). Human serum albumin (HSA) administration was suggested to increase plasma bilirubin-binding capacity. However, its clinical use is infrequent due to difficulties to address its potential preventive and curative benefits, and to the absence of reliable markers to monitor bilirubin neurotoxicity risk. We used a genetic mouse model of unconjugated hyperbilirubinemia showing severe neurological impairment and neonatal lethality. We treated mutant pups with repeated HSA administration since birth, without phototherapy application. Daily intraperitoneal HSA administration completely rescued neurological damage and lethality, depending on dosage and administration frequency. Albumin infusion increased plasma bilirubin-binding capacity, mobilizing bilirubin from tissues to plasma. This resulted in reduced plasma Bf, forebrain and cerebellum bilirubin levels. We showed that, in our experimental model, Bf is the best marker to determine the risk of developing neurological damage. These results support the potential use of albumin administration in severe acute hyperbilirubinemia conditions to prevent or treat bilirubin neurotoxicity in situations in which exchange transfusion may be required.
650    _2
$a zvířata $7 D000818
650    _2
$a bilirubin $x krev $7 D001663
650    _2
$a mozeček $x účinky léků $7 D002531
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a lidé $7 D006801
650    _2
$a novorozenecká hyperbilirubinemie $x krev $x komplikace $7 D051556
650    _2
$a novorozenecká žloutenka $x krev $x komplikace $7 D007567
650    _2
$a myši $7 D051379
650    _2
$a nemoci nervového systému $x etiologie $x prevence a kontrola $7 D009422
650    _2
$a fototerapie $x metody $7 D010789
650    _2
$a sérový albumin $x aplikace a dávkování $7 D012709
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bortolussi, Giulia $u International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149 - Trieste, Italy.
700    1_
$a Schreuder, Andrea B $u Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University of Groningen, Beatrix Children's Hospital-University Medical Center, Groningen, Hanzeplein 1,9713 GZ Groningen, The Netherlands.
700    1_
$a Jašprová, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, U Nemocnice 2, Prague, 120 00, Czech Republic.
700    1_
$a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, U Nemocnice 2, Prague, 120 00, Czech Republic.
700    1_
$a Verkade, Henkjan J $u Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University of Groningen, Beatrix Children's Hospital-University Medical Center, Groningen, Hanzeplein 1,9713 GZ Groningen, The Netherlands.
700    1_
$a Muro, Andrés F $u International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 99 - 34149 - Trieste, Italy.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 5, č. - (2015), s. 16203
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26541892 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161005131804 $b ABA008
999    __
$a ok $b bmc $g 1166308 $s 952624
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 5 $c - $d 16203 $e 20151106 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20161005

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...